Compassionate Use Study of Adalimumab in Children 2 to less than 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA).

Trial Profile

Compassionate Use Study of Adalimumab in Children 2 to less than 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA).

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 13 Jun 2015 Results of post hoc analysis presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Dec 2012 Additional lead trial centre identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top